Sunshine Biopharma Inc. (SBFM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Sunshine Biopharma reported revenue of $36.3M, up 4.1% from $34.9M the year before. Net income was -$6.0M (a -16.5% net margin). Gross margin was 33.8% and operating margin was -17.2%. Operating activities generated -$5.3M of cash, leaving -$5.5M of free cash flow. At fiscal year end, Sunshine Biopharma held $30.1M in total assets against $7.0M in total liabilities.
Open the full interactive Sunshine Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Sunshine Biopharma Key Stats
| Share Price | $0.24 |
|---|---|
| Market Cap | $322,216 |
| Revenue YoY Growth | +4.1% |
| 52-Week Range | $0.24 – $22.00 |
| Shares Outstanding | 1.4 million (basic, 2026 Q2) |
Sunshine Biopharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $71,410 | $228,426 | $4.3M | $24.1M | $34.9M | $36.3M |
| Gross Profit | $45,563 | $110,596 | $1.7M | $8.3M | $10.7M | $12.3M |
| Operating Income | -$576,874 | -$2.4M | -$27.0M | -$4.8M | -$5.8M | -$6.2M |
| Pre-Tax Income | -$2.8M | -$12.4M | -$26.5M | -$4.1M | -$5.4M | -$6.0M |
| Income Tax | — | $0 | $233,304 | $395,166 | -$234,858 | $21,609 |
| Net Income | -$2.8M | -$12.4M | -$26.7M | -$4.5M | -$5.1M | -$6.0M |
| Diluted EPS | — | — | -$35200.00 | -$3800.00 | -$73.20 | — |
Sunshine Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $9.4M | $8.6M | $8.1M | $9.3M |
| Net Income | -$883,820 | -$2.1M | -$1.2M | -$1.6M |
Sunshine Biopharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $989,888 | $2.0M | $21.8M | — | — | — |
| Current Assets | $1.0M | $2.2M | $27.3M | $24.9M | $26.0M | $26.9M |
| Total Assets | $1.0M | $2.2M | $29.2M | $27.3M | $30.6M | $30.1M |
| Current Liabilities | $1.1M | $91,229 | $6.9M | $5.6M | $6.3M | $6.4M |
| Total Long-Term Debt | $1.8M | $1.9M | — | — | — | — |
| Total Liabilities | $2.0M | $2.0M | $7.6M | $6.1M | $7.1M | $7.0M |
| Shareholders' Equity | -$954,837 | $211,662 | $21.6M | $21.2M | $23.5M | $23.0M |
Sunshine Biopharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$657,299 | -$1.8M | -$5.2M | -$8.8M | -$12.5M | -$5.3M |
| Cash From Investing | -$1,191 | $0 | -$14.6M | -$656,150 | -$2.3M | -$836,306 |
| Cash From Financing | $1.6M | $2.9M | $39.5M | $3.4M | $9.3M | $4.7M |
| Free Cash Flow | -$658,490 | -$1.8M | -$5.4M | -$8.9M | -$14.2M | -$5.5M |
Figures from Sunshine Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Sunshine Biopharma financials page for every line item.
Sunshine Biopharma Company Profile
| Ticker | SBFM |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Fort Lauderdale, Florida |
| Incorporated in | Colorado |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001402328 |
Frequently Asked Questions
What was Sunshine Biopharma's revenue in fiscal 2025?
Sunshine Biopharma (SBFM) reported revenue of $36.3M for fiscal 2025.
What is Sunshine Biopharma's annual revenue history?
Sunshine Biopharma's annual revenue by fiscal year: 2020: $71,410; 2021: $228,426; 2022: $4.3M; 2023: $24.1M; 2024: $34.9M; 2025: $36.3M.
What was Sunshine Biopharma's net income in fiscal 2025?
Sunshine Biopharma reported net income of -$6.0M for fiscal 2025.
How much free cash flow did Sunshine Biopharma generate in fiscal 2025?
Sunshine Biopharma generated -$5.5M of free cash flow in fiscal 2025.
What was Sunshine Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Sunshine Biopharma reported revenue of $9.3M.
How many shares of Sunshine Biopharma are outstanding?
Sunshine Biopharma reported a weighted average of 1.4 million basic shares outstanding in 2026 Q2.
What is Sunshine Biopharma's market cap?
Based on its latest closing price, Sunshine Biopharma (SBFM) has a market capitalization of about $322,216.
When does Sunshine Biopharma's fiscal year end?
Sunshine Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Sunshine Biopharma headquartered?
Sunshine Biopharma lists its business address in Fort Lauderdale, Florida in its SEC filings.